Feed

RNA

Avidity Biosciences

RNA · NASDAQ

$10.09 -1.18% (-$0.12)

1M -22.15%

Piotroski F-Score Weak

2/9

Valuation

N/A

EV/EBITDA N/A

P/S N/A

P/B N/A

Growth

N/A

Rev. growth N/A

FCF growth N/A

Book val. growth N/A

Profitability

N/A

Net margin N/A

Op. margin N/A

FCF margin N/A

Quality

N/A

ROE N/A

ROA N/A

Asset turnover N/A

Debt

N/A

Current ratio N/A

Int. coverage N/A

Net debt/EBITDA N/A

Stability

42 /100

Moderate

Beta 0.37x

EPS volatility N/A

Profitable years N/A

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RNA

Online

O podjetju

Avidity Biosciences is a biotechnology company focused on developing advanced therapeutic methods using targeted RNA-based therapies. The company specializes in creating therapeutic products that leverage its proprietary technologies to selectively deliver therapeutic molecules to specific cells, offering a new approach to treating diseases caused by genetic mutations. Avidity focuses on treating diseases such as Duchenne muscular dystrophy and other genetic disorders that previously lacked effective treatments.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Kathleen Gallagher

Employees

511

Headquarters

San Diego

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

57d

⌘ K

StockBot Live

Tržne razmere Wall Street

Wall Street višje na dan odločitve Fed

S&P 500 +0.40% in Nasdaq +0.60% sta se odprla višje. DAX +0.35% je zrasel pred dvigom obrestnih mer Fed.

Vprašajte o tem

StockBot pozna 80,000+ delnic po vsem svetu